Special Feature

User Panel

My Panel

My Panel

Bookmark Science Articles

Recent News
Bookmark / Share This Science Site

Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned.

Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

  • Abstract Text of This Paper
  • Journal Published
  • MeSH Keywords of This Abstract
  • Chemicals and Substances Used in this Paper
  • Grants and Granting Agency of this Research
  • Database Accession Numbers Used in this Paper
  • Related Papers
  • Related Research Tags
  • Rate this Research Paper
  • Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. Abstract Text:

    georges saabGeorges Saab,ali abu-alfaAli Abu-Alfa,

    OBJECTIVE: Nephrogenic systemic fibrosis (NSF) is a rare multisystemic fibrosing disorder that principally affects the skin but may affect other organs of patients with renal insufficiency. The purpose of our study was to identify any common risk factors and determine whether i.v. gadodiamide is associated with the development of NSF. MATERIALS AND METHODS: A retrospective chart review was performed for all 12 patients diagnosed with NSF at our institution between 2000 and 2006 to identify the clinical manifestations, timing, and dose of gadodiamide administration; dialysis records; concurrent medications; comorbid conditions and surgeries; laboratory findings; imaging findings; and clinical outcome. A review of the dialysis and MR records between 2000 and 2006 showed 559 MRI examinations on 168 dialysis patients (including 301 contrast-enhanced examinations). RESULTS: NSF was diagnosed by clinical findings and tissue diagnosis. All 12 patients had renal insufficiency--eight with dialysis-dependent chronic renal insufficiency and four with acute hepatorenal syndrome. All 12 patients developed skin fibrosis within 2-11 weeks after gadodiamide administration. The odds ratio for development of NSF after gadodiamide exposure was 22.3. No other common event or exposure could be found. Four patients had abnormal scintigraphic bone scans with skin and muscle uptake and lower-extremity MRI finding of edema in the muscles, intermuscular fascia, and skin. Despite the fact that 10 patients were dialyzed within 2 days of gadodiamide administration, this did not prevent the development of NSF. CONCLUSION: Development of NSF was strongly associated with gadodiamide administration in the setting of either acute hepatorenal syndrome or dialysis-dependent chronic renal insufficiency.

    Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. Publishing Authors By Initials

    g saabG Saab,a abu-alfaA Abu-Alfa,

    For similar skin and connective tissue diseases: skin diseases research abstracts see: skin and connective tissue diseases: skin diseases research

    PUBMED ID PMID:

    MEDLINE DATE:

    Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. Journal Published:

    PUBLICATION TYPE: Journal Article

    Journal: AJR. American journal of roentgenology

    VOLUME: 188

    Page Numbers: 586-92

    Journal Abbreviation:

    ISSN: 1546-3141

    DAY: 15

    MONTH: Feb

    YEAR: 2007

    Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. Information

    Number of References:

    LANGUAGE: eng

    NlmUniqueID: 7708173

    Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. Keywords Mesh Terms:

    KEYWORDS: Skin Diseases

    MESH TERMS: epidemiology

    Chemical & Substance for Abstract: Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. Information

    Substance Name: Gadolinium DTPA

    Registry Number: 80529-93-7

    Grant and Affiliation Information for Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned.

    AFFILIATION: Department of Radiology, Loma Linda University Medical Center, 11234 Anderson St., MC Room 2605, Loma Linda, CA 92354, USA.

    Country: United States

    United States Research PublicationUnited States Research Publication

    AGENCY:

    GRANT:

    ACRONYM:

    MEDLINETA: AJR Am J Roentgenol

    REFSOURCE: AJR Am J Roentgenol. 2007 Sep;189(3):W16

    DATABASENAME:

    ACCESSION NUMBER:

    Number Hits: 0

    Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned Related Publications

     

    Molecular Station USER Menu

    Welcome to Molecular Station!

    You have to register before you can post on our forums or use our advanced features. Register Now! Its Free and Fast!

    Already registered? Login now below.

    User Name:

    Password:

    Already registered and Forgot your password? Click below to recover it.

    Recover Lost Password

    Join now - it's fast and free!

    Molecular Station is THE largest network of researchers, scientists and science lovers anywhere!

    Research Terms of Usage and Disclaimer
    Home
    Features

    Protocols

    DNA Forum

    Science Forum

    DNA Forum
    Biology Forum

    Science News


    [CaRP] XML error: Invalid document end at line 2

    For more click here:Science News